PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A Phase 1 clinical trial found that a single 100 mg oral dose of MASL was safe and affected OSCC cell morphology, PDPN expression, and immune cell infiltration [PMID:40681758]
Plant lectins, including those from M. amurensis, are reported to suppress cancer cells by inducing apoptosis or autophagy via pathways such as PI3K/Akt and Wnt/beta-catenin [PMID:39830560]
In vitro studies indicate MAA can induce apoptosis in NSCLC cells and enhance paclitaxel-induced cytotoxicity [PMID:25978938]
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 40158854 (2025) — Maackia amurensis seed lectin structure and sequence comparison with other M. amurensis lectins. · The Journal of biological chemistry
- 2.PMID: 27767199 (2016) — Lectin-based lateral flow assay: proof-of-concept. · The Analyst
- 3.PMID: 40681758 (2025) — Effects of Maackia amurensis seed lectin (MASL) on OSCC cell morphology, PDPN expression, growth, and motility in a phase 1 clinical trial. · Journal of cancer research and clinical oncology
- 4.PMID: 15784536 (2005) — Biofilm Formation by Neisseria gonorrhoeae. · Infection and immunity
- 5.PMID: 24658466 (2014) — Cross-platform comparison of glycan microarray formats.